Greg Shelley
Overview
Explore the profile of Greg Shelley including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
93
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Cho H, Zhang Y, Tien J, Mannan R, Luo J, Narayanan S, et al.
bioRxiv
. 2025 Jan;
PMID: 39763898
Inadequate response to androgen deprivation therapy (ADT) frequently arises in prostate cancer, driven by cellular mechanisms that remain poorly understood. Here, we integrated single-cell RNA sequencing, single-cell multiomics, and spatial...
2.
Dong L, Hu C, Ma Z, Huang Y, Shelley G, Kuczler M, et al.
Med Oncol
. 2024 Jun;
41(7):169.
PMID: 38839666
To investigate extracellular vesicles (EVs), biomarkers for predicting lymph node invasion (LNI) in patients with high-risk prostate cancer (HRPCa), plasma, and/or urine samples were prospectively collected from 45 patients with...
3.
Dong L, Hu C, Ma Z, Huang Y, Shelley G, Kuczler M, et al.
Res Sq
. 2024 Apr;
PMID: 38585988
To investigate extracellular vesicles (EVs) biomarkers for predicting lymph node invasion (LNI) in patients with high-risk prostate cancer (HRPCa), plasma and/or urine samples were prospectively collected from 45 patients with...
4.
The S, Schnepp P, Shelley G, Keller J, Rao A, Keller E
Methods Mol Biol
. 2023 May;
2660:85-94.
PMID: 37191792
Innate resistance and therapeutic-driven development of resistance to anticancer drugs is a common complication of cancer therapy. Understanding mechanisms of drug resistance can lead to development of alternative therapies. One...
5.
Shelley G, Dai J, Keller J, Keller E
Bioengineering (Basel)
. 2021 Dec;
8(12).
PMID: 34940365
Multiple methods (e.g., small molecules and antibodies) have been engineered to target specific proteins and signaling pathways in cancer. However, many mediators of the cancer phenotype are unknown and the...
6.
Schnepp P, Ahmed A, Escara-Wilke J, Dai J, Shelley G, Keller J, et al.
BMC Cancer
. 2021 Dec;
21(1):1316.
PMID: 34879849
Background: Overcoming drug resistance is critical for increasing the survival rate of prostate cancer (PCa). Docetaxel is the first cytotoxic chemotherapeutical approved for treatment of PCa. However, 99% of PCa...
7.
de Mattos Barbosa M, Liu H, Huynh D, Shelley G, Keller E, Emmer B, et al.
JCI Insight
. 2021 Mar;
6(9).
PMID: 33769311
Abs that neutralize SARS-CoV-2 are thought to provide the most immediate and effective treatment for those severely afflicted by this virus. Because coronavirus potentially diversifies by mutation, broadly neutralizing Abs...
8.
Schnepp P, Shelley G, Dai J, Wakim N, Jiang H, Mizokami A, et al.
Mol Cancer Res
. 2020 Jun;
18(9):1290-1301.
PMID: 32513898
The majority of patients with prostate cancer treated with docetaxel develop resistance to it. To better understand the mechanism behind the acquisition of resistance, we conducted single-cell RNA-sequencing (scRNA-seq) of...
9.
Smith D, Daignault-Newton S, Grivas P, Reichert Z, Hussain M, Cooney K, et al.
Clin Genitourin Cancer
. 2020 Apr;
18(4):332-339.e2.
PMID: 32299729
Background: Cabozantinib is active in advanced prostate cancer with improvement on bone scans in men on phase II trials. This trial evaluated the efficacy and changes in bone lesions in...
10.
Jiang Y, Dai J, Yao Z, Shelley G, Keller E
Mol Cancer Res
. 2017 Mar;
15(7):875-883.
PMID: 28314844
Integrins that contain an integrin αV subunit contribute to multiple functions that promote cancer progression. The goal of this study was to determine whether abituzumab (DI17E6, EMD 525797), a humanized...